(AOF) – Advicenne announced that its gross sales reached 4.4 million euros in 2023, up 20% year-on-year. This biotech specialist in innovative treatments against rare kidney diseases specifies that this growth in gross sales comes mainly from those of Sibnayal, its main product, which showed an increase of 84% in volume over the entire financial year. In value terms, Sibnayal’s gross sales increased over the same period by 40% to 1.94 million euros.
The difference in growth in value and volume is largely explained by the growing share of sales from partnerships outside France and the structure of transfer prices.
“The year 2023 marked the beginning of the commercial deployment of Advicenne,” underlines general manager Didier Laurens. “Despite a regulatory environment that remains complex regarding the issues of setting prices and obtaining reimbursement, we are particularly satisfied with the evolution of Sibnayal sales.” He specifies that “this is particularly the case in France where the deployment of a sales force has shown a record acceleration (in) sales over several consecutive months” but that “the situation appears, however, to be more mixed in the United Kingdom, penalized by the difficulties of the pharmaceutical market.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.